| Send2Press.com • Today is Monday, February 13, 2012 | A Member of the Neotrope News Network |  |
|
|
NEWS ARCHIVES : U.S. and World News :
Business :
Patent and Trademark
News
|
Press Release:
USPTO Issues a Notice of Allowance for MMDI's BetaWire(TM) Guidewire Patent
 "This is truly break through guidewire technology not seen before," said Steve Nuss, MMDI's Chief Marketing Officer. "Beta Titanium is an ideal alloy for interventional guidewires, its unique properties combine the best attributes found in conventional guidewire alloys such as Nitinol and stainless steel," he added. Interventional Cardiologists that have evaluated the BetaWire for MMDI have been extremely impressed with its performance attributes such as precise one-to-one torque transmission, guidewire advancement, tip shaping and retention, flexibility and kink resistance. MMDI has worked diligently to receive issuance of this U.S. patent. Millions of interventional guidewires are used every year throughout the world and MMDI believes that the BetaWire has the potential to make a significant impact on the market. Separately, MMDI also expects to receive international patent protection for the BetaWire in the very near future. The Company will be seeking potential strategic partners for licensing, sales or distribution of their guidewire technology. Additional information can be obtained by contacting Steve Nuss, Chief Marketing Officer at 763-354-7105 or snuss@2mdinc.com. You may also visit our website at: www.2mdinc.com. About MMDI MMDI was established in 2001 and is based in Plymouth, Minnesota. Located in the heart of Minnesota's "Medical Alley," MMDI has access to some of the world's finest medical product development, manufacturing and marketing resources. The Company's primary objective is to identify, develop, patent and manufacture unique medical devices that provide significant clinical benefits and market opportunities.
NEWS SOURCE: Minnesota Medical Development, Inc.
Send2Press® is the originating wire service for this story. Terms of Use. © Minnesota Medical Development, Inc.. All trademarks acknowledged.
THE CONTENT OF THE ABOVE PRESS RELEASE WAS PROVIDED BY THE NEWS SOURCE (Minnesota Medical Development, Inc.), WHO IS SOLELY RESPONSIBLE FOR ITS ACCURACY. FOR QUESTIONS ABOUT THIS STORY CONTACT THE NEWS SOURCE AND NOT THIS WEBSITE.
Journalist Resources:
Download original press release as issued including media contact information for Minnesota Medical Development, Inc..
Additional News Releases on Similar Topics:
|
Subscribe to Send2Press®
Daily News Releases by E-Mail
Follow Send2Press on Social Sites: 
Additional News from
Minnesota Medical Development, Inc. : » MMDI Announces Agreement with Novation to Supply the Rebound HRD » MMDI's Rebound HRD V Receives FDA 510(k) Clearance » USPTO Issues a Notice of Allowance for MMDI's BetaWire(TM) Guidewire Patent
|
||||||||||||||||||||||||||
View our news channels by industry topics, by U.S. States, or by selected U.S. Cities:
|
Terms of Use and License
This "article format" version of the issued press release is Copr. © 1983-2012 Neotrope/Send2Press. You may freely link to this article version of the press release or may use the release text as the basis for an original article or news posting. If the content is copied verbatim via a scraping or copy/paste method, the news item must be properly "attributed" to Send2Press® Newswire as the originating wire service for this story (may not be posted on ANY site selling/offering SEO or PR services, newswire services, or adult content!). |
DISCLAIMER: the above press release content is believed accurate but not guaranteed, and is based on business news supplied by the source. The noted source is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements. Neotrope/Send2Press (this website) makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news and profiles are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope® or Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.
REFERENCES: USPTO Issues a Notice of Allowance for MMDI's BetaWire(TM) Guidewire Patent, Minnesota Medical Development, Inc., BetaWire guidewire technology patent, interventional guidewire, MMDI, placement of balloon catheters and other diagnostic and therapeutic devices during coronary or peripheral interventional procedures, Interventional Cardiologists, patents, press release, Nov 19, 2008. |
|
THIS PAGE MEDIA READS (by media and public, as of today): 2841 times (1 today, 1 this week, 9 this month, 35 this year)
Site Design and Content is Copr. © 1983 - 2011 Neotrope® - All rights reserved. Send2Press® is a reg. trademark and service mark of NEOTROPE.
Press Release Writing | About Send2Press | Meet Our Staff | Contact Us | Our Services | Help Desk | Legal | Privacy | How-To Articles | RSS Feeds | Journalist Tools | Client eMediaKits | Headline Feeds | Podcast | PR News Channels | Daily News Desk | Success Stories | PRTRax™ Reader Tracking | Targeted News Distribution | Internet Marketing Services | Order PR Services | Terms of Service (TOS)